09.07.2020 QIAGEN N.V.  NL0012169213

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces preliminary results for Q2 2020


DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results
QIAGEN N.V.: QIAGEN announces preliminary results for Q2 2020

09-Jul-2020 / 18:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN announces preliminary results for Q2 2020

Venlo, The Netherlands, July 9, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary sales and adjusted earnings per share results for the second quarter of 2020.

Net sales rose approximately 18-19% at constant exchange rates (CER) from $381.6 million in the same period of 2019, and faster than the outlook for at least 12% CER growth announced on May 5, 2020. The better-than-expected net sales growth reflects very significant demand for solutions used in COVID-19 pandemic testing against weaker customer demand trends in other product areas.

Adjusted earnings per share (EPS) for the second quarter of 2020 are expected to rise approximately 68% to $0.55-0.56 CER based on preliminary results compared with $0.33 CER in the second quarter of 2019 and the outlook of May 5, 2020, of at least $0.40 CER for the same period of 2020.

Based on exchange rates as of June 30, 2020, QIAGEN expects currency movements against the U.S. dollar (reporting currency) to have an adverse impact on results for the second quarter of 2020 of about 2-3 percentage points on net sales at actual rates, and resulting in an adverse impact of approximately $0.01 on adjusted EPS.

QIAGEN continues to experience unprecedented demand for products used in coronavirus testing - in particular RNA sample technology kits, reagents sold to third parties for use in their own kits and cartridges for the QIAstat-Dx syndromic platform. Given the unmet demand from customers around the world, QIAGEN is focused on significantly and continuously expanding production capacity for these products, as well as for new products set to be launched, that are supporting the public health response.

Further information will be provided in the first half of July 2020 when QIAGEN plans to publish a more comprehensive overview of preliminary results for the second quarter and first half of 2020, along with perspectives on anticipated business trends for the third quarter of 2020. In addition, QIAGEN intends to update previously communicated expectations for growth trends for the full year and share incremental perspectives on the potential impact of the coronavirus pandemic on QIAGEN's business. The release of full second quarter 2020 results remains planned for August 4, 2020.

Hulsterweg 82
5912 PL Venlo
The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

Contacts QIAGEN N.V.:
John Gilardi, Tel: +49 2103 29 11711; [email protected]



Forward Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QFT-Plus test for latent TB, its portfolio of next generation sequencing solutions and QIAstat-Dx), net sales in particular geographies, adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of next generation sequencing solutions, the QIAstat-Dx syndromic testing platform, a gastrointestinal panel in the U.S., and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in its portfolio and share repurchase commitments, plans to shift its Global Operations organization to a regional manufacturing structure, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, our determination that our current stand-alone business plan represents the best opportunity for value creation, and plans to take further pre-tax charges in 2020 related to the project announced in Q3 2019, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions, including the announced acquisition by Thermo Fisher Scientific Inc., may not materialize as expected; and the other factors discussed under the heading "Risk Factors" contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


09-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: [email protected]
Internet: www.qiagen.com
ISIN: NL0012169213
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 1090415

End of Announcement DGAP News Service

1090415  09-Jul-2020 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 1.172,31 1.269,77 1.183,21 1.311,96 1.362,88 1.527,26 1.817,00
EBITDA1,2 336,02 295,98 308,71 413,21 183,32 482,95 0,00
EBITDA-Marge3 28,66 23,31 26,09 31,50 13,45 31,62 0,00
EBIT1,4 160,79 93,79 128,06 232,88 -23,34 315,55 0,00
EBIT-Marge5 13,72 7,39 10,82 17,75 -1,71 20,66 0,00
Jahresüberschuss1 116,10 76,78 33,72 166,31 -37,01 293,30 0,00
Netto-Marge6 9,90 6,05 2,85 12,68 -2,72 19,20 0,00
Cashflow1,7 290,56 324,18 239,39 314,04 295,40 373,83 0,00
Ergebnis je Aktie8 0,96 0,83 1,06 1,17 -0,16 1,25 1,90
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2DKCH 46,520 Halten 10.924,48
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
22,15 27,96 0,78 64,17
4,78 29,22 7,15 24,86
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
0,00 0,00 0,00 29.06.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
03.05.2021 12.07.2021 27.10.2020 30.04.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,66% 8,67% 8,34% 11,11%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu QIAGEN N.V.  ISIN: NL0012169213 können Sie bei DGAP abrufen

Biotechnologie , A2DKCH , QIA , XETR:QIA